Local and international expert opinions on KEYNOTE-045 in advanced urothelial carcinoma

GU cancer

22 Mar 2021

Watch Dr Krieger and Professor Bellmunt provide commentary and insights on the KEYNOTE-045 study, in patients with locally advanced and metastatic urothelial cancer post progression on platinum-containing chemotherapy, and the relevance to patients in Australia.

In this 3 chapter video series Sydney-based medical oncologist Dr Laurence Krieger and lead author of the KEYNOTE-045 study, Professor Joaquim Bellmunt, provide comments on KEYNOTE-045 and share their perspectives on the initial analysis as published in The New England Journal of Medicine 2017, and the updated 3-year analysis, as poster presented at ESMO 2019. Dr Krieger also discusses the secondary endpoint data from this trial and discusses approaches to managing certain locally advanced and metastatic urothelial cancer patients in Australia.

Developed by MSD Australia. These are the opinions of Dr Laurence Krieger and Professor Joaquim Bellmunt and do not necessarily represent those of MSD Australia. Please review the appropriate product information before prescribing any treatment mentioned in this video.

Dr Laurence Krieger, Consultant Medical oncologist Genesis Care, Consultant General Physician, Royal North Shore Hospital and clinical lecturer University of Sydney, Northern Medical School.

Joaquim Bellmunt Molins, MD, PhD, Senior Researcher PSMAR/IMIM, Hospital del Mar, Associate Professor of Medicine. Harvard Medical School

Already a member?

Login to keep reading.

Email me a login link